China Biologic Products Inc. (NASDAQ:CBPO) shares saw an uptick in trading volume on Friday . 259,438 shares changed hands during trading, an increase of 5% from the previous session’s volume of 247,744 shares.The stock last traded at $112.03 and had previously closed at $110.57.

A number of brokerages recently issued reports on CBPO. Zacks Investment Research raised China Biologic Products from a “hold” rating to a “buy” rating and set a $141.00 price target on the stock in a research report on Wednesday, August 10th. Jefferies Group increased their price target on China Biologic Products from $136.00 to $155.00 and gave the stock a “buy” rating in a research report on Friday, August 5th. Finally, Credit Suisse Group AG raised China Biologic Products from a “neutral” rating to an “outperform” rating in a research report on Tuesday, July 5th.

The firm’s 50 day moving average price is $117.43 and its 200 day moving average price is $115.38. The firm has a market cap of $3.02 billion and a PE ratio of 32.33.

China Biologic Products (NASDAQ:CBPO) last announced its earnings results on Thursday, August 4th. The biopharmaceutical company reported $1.26 earnings per share for the quarter, topping analysts’ consensus estimates of $1.16 by $0.10. During the same quarter in the previous year, the firm earned $1.06 EPS. The business earned $91.40 million during the quarter, compared to analysts’ expectations of $87.60 million. China Biologic Products’s quarterly revenue was up 15.6% on a year-over-year basis. On average, analysts expect that China Biologic Products Inc. will post $4.34 earnings per share for the current year.

In other news, Director Wp X. Biologics Llc sold 2,775,000 shares of the business’s stock in a transaction that occurred on Wednesday, June 8th. The stock was sold at an average price of $111.00, for a total value of $308,025,000.00. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, CFO Ming Yang sold 21,092 shares of the business’s stock in a transaction that occurred on Monday, August 15th. The stock was sold at an average price of $124.32, for a total value of $2,622,157.44. Following the completion of the transaction, the chief financial officer now owns 24,782 shares in the company, valued at approximately $3,080,898.24. The disclosure for this sale can be found here.

China Biologic Products, Inc (China Biologic) is a biopharmaceutical company. The Company is principally engaged in the research, development, manufacturing and sales of human plasma-based biopharmaceutical products in China. It operates in the manufacture and sales of human plasma products segment. It has a product portfolio with over 20 various dosage forms of plasma products and other biopharmaceutical products across over nine categories.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.